Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe
Treatment patterns generally followed guidelines. ARPi prescriptions prior to mCRPC were numerically higher than previously reported, however HRRm testing rates were still low meaning mCRPC patients may miss out on more effective targeted treatments.
Authors
- Chinelo Orji (ORCID: https://orcid.org/0000-0002-2335-0121)
- Jake Butcher
- Sameer R. Ghate (ORCID: https://orcid.org/0000-0001-8555-6363)
- Elena Castro (ORCID: https://orcid.org/0000-0002-3691-6454)
- Amanda Ribbands (ORCID: https://orcid.org/0000-0001-9819-8737)
- Weiyan Li (ORCID: https://orcid.org/0000-0002-1803-8088)
- Maria Walley
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- Hospital Universitario 12 De Octubre (ES)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1080/14796694.2025.2470616
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.59